IMNM Stock Overview
A biotechnology company, develops targeted cancer therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Immunome, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.91 |
| 52 Week High | US$30.96 |
| 52 Week Low | US$6.93 |
| Beta | 1.82 |
| 11 Month Change | -19.73% |
| 3 Month Change | -26.79% |
| 1 Year Change | 23.97% |
| 33 Year Change | -42.41% |
| 5 Year Change | n/a |
| Change since IPO | -26.36% |
Recent News & Updates
Recent updates
Immunome: Why It Has Doubled Over The Last Month
Jan 18Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?
Mar 17
Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?
Nov 20Immunome GAAP EPS of -$0.74
Aug 05Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation
Aug 05Immunome gains 34% after preclinical data on COVID-19 antibody
Jun 30We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth
Feb 21Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth
Oct 02Immunome launches $27M private placement
Apr 26Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?
Mar 12Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares
Jan 18Immunome EPS misses by $7.22
Nov 17Shareholder Returns
| IMNM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.7% | -10.9% | -2.2% |
| 1Y | 24.0% | 13.9% | 30.1% |
Return vs Industry: IMNM exceeded the US Biotechs industry which returned 20.8% over the past year.
Return vs Market: IMNM underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| IMNM volatility | |
|---|---|
| IMNM Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMNM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMNM's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 105 | Clay Siegall | immunome.com |
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc. Fundamentals Summary
| IMNM fundamental statistics | |
|---|---|
| Market cap | US$695.32m |
| Earnings (TTM) | -US$305.35m |
| Revenue (TTM) | US$10.13m |
61.0x
P/S Ratio-2.0x
P/E RatioIs IMNM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMNM income statement (TTM) | |
|---|---|
| Revenue | US$10.13m |
| Cost of Revenue | US$91.13m |
| Gross Profit | -US$81.00m |
| Other Expenses | US$224.35m |
| Earnings | -US$305.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.89 |
| Gross Margin | -799.64% |
| Net Profit Margin | -3,014.59% |
| Debt/Equity Ratio | 0% |
How did IMNM perform over the long term?
See historical performance and comparison